What a dreamer. The technology is still in serious question. This is exactly why the 7-1 split has tanked.
Show me data and I'll show you a valid stock value.
Did I hear Humira and Abbvie as a potential partner? Due to Humira coming off patent will Abbvie jump into the clinic with Tethadur? I'll be watching for sure.
The best CC I've ever heard from Paul. Focused, Detailed, Upbeat and thorough. I can't wait for the coming months and next year will rock. Though we missed on the quarter, the year was in at .21 cents a (diluted) share. I see next year coming with the start of Iluvien revenue in the US, then mid year rock solid data from Medidur PIII. Investors should be happy about the upbeat Tethadur insight Paul gave us. At some point, one of the bigs is going to step up for a clinical gig for biologic delivery with Tethadur because a sustained delivery platform for Lucentis or Eylea will take even more market share, or allow Lucentis to finally compete with Eylea. So do think there will be some head room for MC growth?
Kool, After a quick shout to Beverly.....it was the 3 month pain reliever for the knee (regarding FLXN). So, that does put pSivida in a position where the arena has been cleared a bit by the competitors. Let's hope HSS/PSDV has a strong announcement for the specific indication they're after........with a big partner like Zimmer.
Kool, Sorry about your position here. Looks like an after hour hit. Was this their intra-articular pain relief indication? If so, Medidur starts looking better and better. Hope PSDV success balances the hit bud.
It seems the Flexion extended release profile is 3 months. Now, wouldn't it be better if it were 6 or 12 months? Just saying it could be the Durasert/ HSS product could be better due to Duraserts ability to provide micrograms of anti-inflammatory to the site over years, not months. That might be the game changer for the pSivida / HSS gig. But until they announce it we got squat and Flexion is in the spotlight.
Frank, We all get it. It's been a tough ride. Our investment thesis and the timeline for it does not jive with those that run the company. Building stockholder value has not been a priority for the company. Though I do believe in the Medidur platform and it's ability to deliver a myriad of small molecules, I thought the Tethadur platform would have shown more clinical interest. Who really knows what's happened with the "enormous promise" aspects of the platform. Granted, this is science and development must be slow and steady. Just thought the slow and steady part has come and gone a bit. No license deals for either platform and a year after Iluvien platform approval by the FDA. The enormous promise aspects would have shown more interest with the fact that "big pharma" would have stepped in and done a deal. Both Alimera and pSivida now have a shared MC of less than 265Million. A bit of a surprise to me.
I expect a high cash burn along with last quarter JD. With the 25 Million milestone from ALIM, there were expenditures left on the back burner; like work on the PFE Latanoprost gig. So, it will be interesting to hear what Paul has to say and see whether the cash burn has tapered off or is up like last quarter. I'm curious whether the new evaluation agreements gave pSivida a bit of cash influx too. GLTA, we'll need it.
Terry, There is no question as to the validity of the Iluvien-Medidur concept, in delivering drugs on site with micrograms of therapeutic on a daily basis over years. It just may be the ticket to Dry AMD too. pSivida has said they are interested in pursuing this strategy " on their own". But let's face it, a global partner would go far in creating a financial foundation through the clinical phases. I know that Medidur is what pSivida is driving the developmental narrative with, Something has to give and soon. The Alimera story won't hurt in the least. On a side note, ALIM shares sure looked good last week. GL
Kool. Caught that too. Someone always knows something. Let's not get too excited but it's better up after all the days of uncertainty. I'd like to finally hear of an HSS gig with a big partner. That would move the needle and get the mojo going in the right direction. Funny, heavier than normal volume is 150K shares.